PRAX Relutrigine: $9.6B SCN2A/SCN8A Epilepsy Primer

Praxis Precision Medicines (PRAX) enters the home stretch on relutrigine at $344.75 a share and a $9.6 billion market cap, after the FDA pushed the drug’s PDUFA date from September 27 to December 27, 2026. Relutrigine would be the first approved therapy for SCN2A and SCN8A developmental and epileptic encephalopathies, a pair of ultra-rare pediatric seizure disorders with no targeted treatment today. The stock is a genuine binary, but it is a binary where the market has already priced in both the relutrigine approval and a second near-approval product, ulixacaltamide for essential tremor. The approval odds sit above 80%. The problem is that a clean win may not move a $9.6 billion stock that is already trading at par with revenue-generating rare disease peers.

The disease is the reason this approval matters. SCN2A and SCN8A encephalopathies are caused by gain-of-function mutations in sodium channel genes, producing intractable seizures that begin in infancy and come with profound developmental delay. There is no approved drug for either condition. Families manage with off-label antiseizure medications that blunt seizures without addressing the underlying channel dysfunction, and many children never achieve meaningful seizure control. The prevalence is small, on the order of a few thousand patients in the United States across both genes, with SCN8A incidence reported at just over 1 in 56,000 births and SCN2A similarly rare. Most children never outgrow the seizures, and the developmental consequences are permanent, which is why a therapy that actually quiets the channel is worth so much to these families. That rarity is exactly why the FDA granted relutrigine Breakthrough Therapy Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation, and why approval carries a Priority Review Voucher worth roughly $100 million on the secondary market.

Relutrigine, also called PRAX-562, is a sodium channel modulator that targets the persistent sodium current driving the hyperexcitable state in these mutations. The mechanism is the point. Unlike broad antiseizure drugs, relutrigine is designed to hit the specific ion channel defect that causes the disease, which is why Praxis frames it as disease-modifying rather than merely symptomatic. That framing matters more for the valuation than for the label, because investors are not paying for a niche antiseizure drug. They are paying for a precision-medicine platform story in epilepsy, the same story Praxis is running with its antisense and small molecule platforms across four late-stage programs. The nearest approved analog in the space is fenfluramine, a serotonergic and sigma-1 receptor modulator cleared for Dravet and Lennox-Gastaut syndrome, but relutrigine is aimed at a different mechanism and a narrower, more genetically defined population, which is precisely the kind of asset the FDA’s expedited review pathway was built for.

The clinical data is strong for a rare disease. In the Phase 2 EMBOLD study (NCT05818553), relutrigine produced a 46% placebo-adjusted reduction in countable motor seizures over the 16-week double-blind period, and 33% of patients were seizure-free at the data cut with the longest follow-up exceeding 200 days. In the open-label extension, the median reduction in motor seizures hit 75%, and by month 11 patients showed roughly 90% seizure reduction from baseline. The mean period between seizures stretched from three days at baseline to 67 days at month 11. Those are the kind of numbers that get a drug Breakthrough Therapy Designation and a Priority Review, and they are the reason Praxis filed an NDA on Phase 2 data rather than waiting for a confirmatory Phase 3.

The extension is the yellow flag. In June, the FDA told Praxis it was extending the PDUFA by three months because Praxis had submitted additional sensitivity analyses of existing clinical data, which the agency deemed a major amendment. No new clinical studies were requested, and the FDA cited no safety or manufacturing concerns. Then, in its August second-quarter report, Praxis said the mid-cycle meeting was complete and the FDA identified no major safety or efficacy issues and does not plan an advisory committee meeting. Read together, the extension looks more like a statistics and paperwork review than a fundamental problem with the drug. But an extension is never good news, and a drug filed on Phase 2 data always carries the tail risk that the agency decides it wants confirmatory data in hand before a full approval rather than an accelerated one. The original September 27 date and its shift are tracked in the September PDUFA calendar, and the new December 27 date lands in the Q4 FDA calendar.

The economics do not stop at relutrigine. Praxis has a second late-stage asset, ulixacaltamide for essential tremor, which also completed its mid-cycle review with no advisory committee planned and is building commercial infrastructure for a launch. The company holds $1.4 billion in cash as of June 30, 2026, enough to fund operations into 2028, against a net loss of $83.7 million in the second quarter. On approval, relutrigine earns a Priority Review Voucher that Praxis can monetize for roughly $100 million, a meaningful offset to launch spend. So this is not a one-asset binary. It is a two-product commercial transition, and the market is treating it like a growth story rather than a pair of coin flips.

The valuation is where the line is drawn. Praxis trades at $9.6 billion with zero revenue and two unapproved drugs. Stoke Therapeutics (STOK), the closest comp in rare pediatric epilepsy, is developing zorevunersen for Dravet syndrome and trades at $2.04 billion. Praxis is worth 4.7x Stoke despite both being pre-revenue rare epilepsy companies, a gap that only makes sense if you fully price in relutrigine approval, ulixacaltamide approval, and successful launches for both. Ionis (IONS), which has actual revenue and a diversified rare disease pipeline including its own PDUFA catalyst, trades at $10.15 billion. Praxis at $9.6 billion is effectively at par with Ionis with a fraction of the revenue base and none of the commercial track record. That is a full price, and it is the core of the hesitation.

The reimbursement environment is the risk that sits on top of everything else. Both drugs are launching into a market where rare disease pricing is under pressure from payers and from the Inflation Reduction Act’s drug pricing provisions, so peak sales estimates that assume premium rare disease pricing may not survive negotiation. The extension is the nearer-term tell: it could foreshadow a label that requires a confirmatory study or restricts the initial indication to a narrower patient slice, which would reset launch expectations. And the second product is no sure thing. Essential tremor is a crowded, price-sensitive primary care market, and ulixacaltamide’s own tolerability data suggests roughly 30% of patients experience early side effects that could slow adoption. The PDUFA trading playbook is worth reviewing before sizing this, because this is a case where the run-up may have already happened.

The verdict is a hold into the December decision, not a chase. The clinical data supports approval, the mid-cycle signal is clean, and the cash runway removes the near-term existential risk. But at $9.6 billion the stock has already paid for both approvals and a chunk of the launches. If relutrigine is approved with a clean label, the stock likely re-rates toward $11 billion to $12 billion as the DEE launch begins and the voucher is monetized. If the extension was the first hint of a restricted label, the stock gives back 25% to 35%, because a $9.6 billion valuation has no cushion for a soft launch. The better trade is to own this after the December label is in hand rather than bet $9.6 billion of someone else’s money that a Phase 2 filing turns into a clean first-in-disease approval without a hitch.